Group: Coating
Group: Cellulose
Microcrystalline cellulose (MCC) is a refined wood pulp that is commonly used as a texturizer, anti-caking agent, and bulking agent in food and dietary supplements. It is a white, odorless powder that is insoluble in water and is often used to improve the texture and stability of products.
Also known as: Cellulose, MCC
Group: Rhubarb
Also known as: ERr 731, Siberian Rhubarb root, ERr 731(TM), ERr 731(R)
Group: Stearic Acid
Also known as: C18:0
UNII Code: 4ELV7Z65AP
Estrovera's key ingredient, ERr731, has been used safely and effectively for over 20 years and is supported by clinical studies.
Estrovera provides relief for multiple menopausal symptoms, including hot flashes, sleep disturbances, mood swings, irritability, anxiety, and sexual problems. Visit MetaDispensary.com for additional information.
Directions: Take one tablet with food and a glass of water once daily at the same time of day or as directed by your healthcare practitioner.
This product is non-GMO, gluten-free, and vegetarian.
This product is non-GMO, gluten-free, and vegetarian.
Caution: Do not use if pregnant or nursing. If taking medication, consult your healthcare practitioner before use.
This product is contraindicated for individuals with any known or suspected estrogen-dependent cancer.
Storage: Keep tightly closed in a cool, dry place.
GF Certified gluten-free
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Featuring ERr 731
Plant-derived menopausal hot flash relief
8 7-Tablet Bottles
Dietary Supplement
Highly Efficacious Formulated with ERr 731, which has shown up to 83% reduction in menopausal symptoms
Exceptional safety profile ERr 731 recommended by healthcare professionals in Europe since 1993
Extensively studied Multiple well-designed, randomized, double-blind placebo-controlled studies
Simple dosing Well-tolerated, once-daily tablet
This estimated ratio is not included in the publication of cumulative results of a 12-week study followed by 2 48-week observational studies (OS). It is calculated from the mean change of the MRS II total score of 5.7 at the end of the first 48-week OS divided by the baseline score of 34. There was no change in total score from the end of the first OS to the end of the second OS. These results are from the ERr 731 subgroup only, which was administered ERr 731 daily for a total of 108 weeks. This calculation does not take into account some changes in study population over time.
83% decrease in daily hot flashes ERr 731 delivers non-hormonal hot flash relief, with up to an 83% decrease in daily hot flashes and other menopausal symptoms.
12-week study of 112 perimenopausal women
ERr 731 subjects reported a significant decrease in the median number of daily hot flashes compared to subjects taking placebo
Kaszkin-Bettag M, Ventskovsky BM, Solskyy S, et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med. 2009; 15(1):24-34.
If you notice any false or inaccurate information in our product listings, please contact us so we can correct it.
Discover more products from our collection
